Scan: When will the FDA approve Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema? — Before July 2027

date	predicted	market price	confidence
2026-09-08	57%	37%	56%

1. Planner Fable 5.1 · Fermi decomposition + tool plan

Tools chosen: kalshi_direct kalshi_related polymarket_related article_search claude_news earnings_data wikipedia code_execution

Sub-questions (Fermi decomposition)

Has the Phase 3 HAELO trial of lonvo-z reported topline data, and did it meet its primary endpoint with a clean safety profile?
Has Intellia submitted (or given a firm date for) the BLA for lonvo-z, and what is the current guided submission timing?
Will lonvo-z receive priority review (~8 month PDUFA) versus standard review (~12 months), given its RMAT/Breakthrough/Orphan designations, and what PDUFA date does that imply relative to July 1, 2027?
Has the FDA clinical hold on Intellia's nex-z (NTLA-2001) for liver toxicity had any regulatory impact on lonvo-z (e.g., partial hold, additional safety data requests, delayed submission)?
What is the historical base rate of first-cycle FDA approval and on-time PDUFA action for novel gene-editing/gene therapy BLAs, and how often are PDUFA dates extended by 3 months?
Does Intellia have sufficient cash runway and CMC readiness to reach and complete the BLA review without delays?

Planner reasoning

Lonvo-z (NTLA-2002) is Intellia's in vivo CRISPR therapy for HAE; approval before July 2027 hinges almost entirely on the timeline chain: Phase 3 HAELO readout -> BLA submission (guided for 2026) -> priority vs standard review -> PDUFA date, plus any spillover from the nex-z liver-safety clinical hold. The Kalshi price is the primary anchor, with sibling date-bucket markets giving an implied timeline distribution; news and NTLA company data fill in the actual regulatory milestones.

2. Research Parallel tool calls

tool	status	time	items	summary
kalshi_direct	OK	0.2s	1	## This Market's Kalshi Data Before July 2027 (KXFDAAPPROVALDATENTLA-LONV-27JUL01) - Current price (probability): 85.00% - 7-day price change: +55.00% - 30-day price change: +58.00% - Average daily volume: 209 contracts - Price range: 27.00% - 97.00% - Data points: 14 days
kalshi_related	OK	2.0s	0	0 related markets / summaries. series KXFDAAPPROVALDATENTLA: 0 markets (skipped 3 no-signal) \| keyword 'lonvo-z': no matches \| keyword 'Intellia': no matches \| keyword 'hereditary angioedema': no matches
polymarket_related	OK	2.0s	0	Scanned 100 active Polymarket markets, kept 0 matches. keyword 'Intellia': 0 markets \| keyword 'lonvo-z': 0 markets \| keyword 'hereditary angioedema FDA': 0 markets
article_search	OK	2.4s	34	Fetched 34 unique articles across 4 queries (lookback=180d). 'Intellia lonvo-z HAELO Phase 3 topline results': 10 articles \| 'Intellia BLA submission lonvoguran ziclumeran FDA': 10 articles \| 'Intellia nex-z clinical hold liver toxicity impact NTLA-2002': 10 articles \| 'lonvo-z priority review PDUFA
claude_news	OK	21.6s	13	Here are the key findings on Intellia's lonvo-z (lonvoguran ziclumeran, NTLA-2002) regulatory timeline for hereditary angioedema: - Phase 3 HAELO topline results (April 27, 2026): The trial met primary and all key secondary endpoints with favorable safety and tolerability data, and a single do
earnings_data	OK	2.0s	1	Fetched FMP data for 1 ticker(s).
wikipedia	OK	2.0s	3	Fetched 3 Wikipedia entries (0 missing pages).
code_execution	OK	45.4s	0	## Quantitative Findings: FDA Approval of Lonvo-z (HAE) Before July 1, 2027 Scenario setup: BLA submission spread across Jun–Dec 2026 (weights 20/30/30/20%); review split 80% priority (~8 mo: 60-day filing + 6 mo review) / 20% standard (~12 mo: 60-day filing + 10 mo review); 17.5% avg chance of

3. Evidence Brief Sonnet 5 · 5455 chars

# Current state Intellia's lonvo-z BLA for HAE was accepted by FDA with Priority Review and a PDUFA target action date of **March 10, 2027** (confirmed via company press release, 2026-09-08) — roughly 3.5 months before the July 1, 2027 cutoff. Resolution requires the FDA to actually approve (not just review) before that date; a Complete Response Letter or major-amendment extension are the main residual risks. # Timeline of key events - 2026-04-27: Phase 3 HAELO topline results reported — met primary and key secondary endpoints, favorable safety (confirmed, ir.intelliatx.com/CNBC). - 2026-04-27: Intellia initiated rolling BLA submission to FDA under RMAT designation (confirmed, ir.intelliatx.com). - 2026-06-13: Detailed HAELO efficacy data presented (EAACI/NEJM) — 87% reduction in monthly attacks vs placebo (p<0.0001); 62% attack/therapy-free at 6 months vs 11% placebo (confirmed). - 2026-08 (approx.): Nex-z (separate program) clinical hold resolved/enrollment resumed; company stated no impact on lonvo-z timeline (confirmed, company statements). - 2026-09-08: FDA accepted completed BLA and granted **Priority Review**, PDUFA date **March 10, 2027**; no advisory committee planned (confirmed, ir.intelliatx.com, MarketScreener). - Ongoing: Company guides to US launch in 1H 2027 if approved; cash runway into 2028 (confirmed, Q2 2026 earnings, ~$628M cash as of 2026-06-30). # Event Will the FDA approve lonvo-z (Intellia) for Hereditary Angioedema before July 1, 2027? # Outcomes to forecast Yes / No # Kalshi market anchor **Current YES price: 85%**, up +55pts over 7 days and +58pts over 30 days — reflecting the Sept 8, 2026 BLA-acceptance/Priority-Review news. Thin liquidity (avg 209 contracts/day); price range historically 27%–97%, indicating high volatility as news landed. This is the consensus to beat. # Sub-question answers 1. **HAELO topline/endpoint/safety** — Yes: met primary endpoint (87% reduction in monthly attacks, p<0.0001) and key secondaries with favorable safety, reported 2026-04-27 and detailed 2026-06-13 (ir.intelliatx.com, NEJM/EAACI). 2. **BLA submission/timing** — Rolling BLA initiated 2026-04-27; completed submission accepted by FDA 2026-09-08 (confirmed). 3. **Priority vs standard review / PDUFA date** — Priority Review granted; PDUFA target action date **March 10, 2027** (confirmed, ir.intelliatx.com). No adcomm planned. 4. **Nex-z clinical hold impact** — No impact reported; nex-z hold was resolved separately and enrollment resumed; lonvo-z reached BLA acceptance milestone independently (company statements). 5. **Historical base rates** — Not directly quantified in research; generic gene-therapy/BLA first-cycle approval and PDUFA-extension base rates were modeled generically by code_execution tool (pre-dating confirmed PDUFA date), less reliable than the now-confirmed March 10, 2027 date. 6. **Cash runway/CMC readiness** — Cash ~$628M as of 2026-06-30, guided to fund operations into 2028, beyond planned 1H2027 launch (quiverquant.com) — no funding gap risk identified. # Key facts (high-confidence, factual) 1. [ir.intelliatx.com] BLA accepted with Priority Review; PDUFA date March 10, 2027. 2. [ir.intelliatx.com/NEJM] HAELO Phase 3 met primary endpoint with strong effect size and clean safety. 3. [company statements] Cash runway into 2028; no funding constraint on review completion. 4. [company statements] Nex-z hold unrelated to lonvo-z regulatory path. 5. [FDA/company] No advisory committee meeting planned — reduces delay risk. # Cross-market signals - Kalshi related: none found (series/keyword searches empty). - Polymarket: no matching markets found. - Sportsbook implied: N/A (not applicable to FDA approvals). # Analyst opinions and speculation - Morgan Stanley and other sell-side biotech notes (unrelated tickers referenced in generic sweep) show general bullishness on gene-editing catalysts but no lonvo-z-specific analyst PDUFA commentary was captured directly. - Company management (CEO) publicly framed RMAT designation as predictive of priority review, which materialized — supports management credibility on timeline guidance. # Directional lean per outcome - **Yes**: PDUFA date (March 10, 2027) sits ~3.5 months before cutoff; even a full 3-month major-amendment extension (June 10, 2027) would still clear before July 1, 2027. Priority review, RMAT, strong topline data, no adcomm, adequate cash all support approval and timely action. - **No**: Residual risk of Complete Response Letter (first-cycle CRLs occur meaningfully for novel modalities, esp. first-in-class in vivo CRISPR); possible CMC/manufacturing inspection issues; any extension beyond 3 months (rare but possible) could push past cutoff. # Gaps / unknowns - No independent base-rate data specific to in vivo CRISPR/gene-editing BLA first-cycle approval rates was retrieved. - No confirmation of manufacturing site inspection status or any FDA information requests since acceptance. - Kalshi/Polymarket cross-market corroboration unavailable (no related markets found). # Calibration anchors - Kalshi current YES price: **85%** (anchor, post-news). - PDUFA date March 10, 2027 provides ~3.5-month buffer to cutoff, larger than typical single 3-month extension — strongly favors Yes. - Priority-review, RMAT/Orphan products with strong single pivotal trial data historically see first-cycle approval rates broadly in 70-85% range (general biologics precedent, not lonvo-z specific).

4. Forecasters Fable 5.1 + GPT-5.6 Sol · in parallel

claude-fable-5-1

62% conf

Yes	82%
No	18%

The BLA was accepted with Priority Review and a confirmed PDUFA date of March 10, 2027, leaving a ~3.5-month buffer before the July 1 cutoff — enough to absorb even a full 3-month major-amendment extension (June 10). HAELO data are strong (87% attack reduction, p<0.0001, clean safety), RMAT/orphan status, no adcomm, and adequate cash all favor first-cycle approval, consistent with historical 70-85% first-cycle rates for priority-review biologics. Residual 'No' risk centers on a CRL for a first-in-class in vivo CRISPR product (CMC/manufacturing inspection issues are the classic cause) and recent CBER unpredictability with surprise CRLs and missed PDUFA dates. I anchor near the Kalshi 85% and shade slightly lower for novel-modality CMC risk.

gpt-5.6-sol

74% conf

Yes	87%
No	13%

HAELO’s 87% attack reduction, favorable safety, and successful BLA acceptance point toward Yes because the clinical package appears compelling. Priority Review, no planned advisory committee, and a March 10, 2027 PDUFA date point toward Yes because even a standard three-month extension would remain before the cutoff. The resolved nex-z hold and cash runway into 2028 remove two potential timeline risks. I place Yes slightly above the 85% Kalshi anchor, while retaining 13% for a first-cycle CRL or atypical delay driven by CMC, inspections, or the novelty of in vivo CRISPR.

5. Devil's Advocate Sonnet 5 · red-team critique

Both forecasters cite "70-85% historical first-cycle approval rates" but this range is explicitly flagged in the brief as "general biologics precedent, not lonvo-z specific" and doesn't account for the unique CMC risks of in vivo CRISPR gene-editing therapies, which have a much thinner track record (only Casgevy as precedent) — neither forecaster adjusts for this reference-class mismatch, instead anchoring too heavily on generic biologic base rates.

Neither forecast explicitly addresses the "No advisory committee planned" fact as a distinct, strong positive signal (adcomm meetings are a common source of both delay and rejection risk) — this should push probability higher than a simple anchor-and-shade approach, yet Forecast 1 shades below the anchor despite this being a strengthening rather than weakening factor since the anchor was set.

The brief notes "recent CBER unpredictability with surprise CRLs and missed PDUFA dates" (Forecast 1's own language) but this claim is not sourced or quantified anywhere in the evidence brief — this appears to be an unsupported assertion imported into the rationale without corroboration, inflating the perceived "No" case artificially.

Both forecasters converge tightly around the 85% Kalshi anchor (82% and 87%) without independently stress-testing the CMC/manufacturing inspection risk highlighted as a genuine unknown in the brief ("No confirmation of manufacturing site inspection status or any FDA information requests since acceptance") — given this is flagged as the single largest unresolved risk factor, more probability mass or explicit reasoning on inspection-driven CRL scenarios would be warranted rather than a generic CMC caveat.

Neither forecast considers the asymmetry in the extension scenario: a "major amendment" 3-month extension pushes PDUFA to June 10, comfortably before July 1, but does not address whether a second/compounding delay (e.g., extension plus a few additional weeks of internal processing before public announcement) could still breach the cutoff — this compounding-delay tail scenario is unquantified in both rationales despite being the most likely mechanistic path to "No."

Both forecasts treat management's credibility ("CEO publicly framed RMAT designation as predictive of priority review, which materialized") as supportive, but this is a single data point of one correct prediction and shouldn't meaningfully inform confidence in the ultimate approval decision, which rests with FDA reviewers, not company guidance — slight overweighting of company-source credibility versus regulatory-agency independent risk.

6. Aggregator Fable 5.1 · final calibrated forecast

83% (68% confidence)

Yes: 83% No: 17%

The confirmed Priority Review PDUFA date of March 10, 2027 leaves a ~3.5-month buffer, so even a full 3-month major-amendment extension (to June 10) resolves Yes; the mechanistic path to No is essentially a first-cycle CRL. HAELO data are unusually strong (87% attack reduction, clean safety), there is no adcomm, and cash/nex-z issues are non-factors, all supporting first-cycle approval. However, the critique correctly notes that the generic 70-85% biologics base rate overstates confidence for a first-in-class in vivo CRISPR product from a first-time BLA sponsor reviewed by CBER, where CMC/manufacturing-inspection CRLs (e.g., Rocket, Ultragenyx, Regenxbio precedents) are the dominant failure mode and inspection status is unconfirmed. Balancing the strong clinical/timeline case against real novel-modality CMC risk, I land slightly below the thin-liquidity Kalshi anchor at 83% Yes.

Pipeline Timing

Total pipeline time: 139.5s

Per-tool research timings shown in the Research section above.